Please login to the form below

Regeneron

This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Pfizer launches early study of COVID-19 antiviral therapeutic

With its antiviral candidates, Pfizer is now aiming to enter the COVID-19 therapeutic space, where Regeneron and Eli Lilly have largely dominated so far. ... Regeneron’s antibody cocktail ( casirivimab and imdevimab) has been granted an emergency use

Latest news

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Roche and Regeneron’s COVID-19 antibody cocktail has demonstrated positive results in a phase 3 trial assessing the investigational treatment in infected non-hospitalised patients. ... Regeneron, the company that has commercialisation responsibilities
Sanofi, Regeneron's Libtayo shows marked reduction in risk of death in cervical cancer patients

Sanofi and Regeneron plan to submit their PD-1 inhibitor Libtayo to regulatory authorities this year for the treatment of advanced cervical cancer, after stopping a phase 3 trial early on ... Sanofi and Regeneron said in a statement that, based on the
UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

Following this, the IDMC has recommended halting enrolment into the placebo group, which Regeneron said it will do ‘immediately’. ... In January, Regeneron announced that the antibody cocktail can be used as a passive vaccine to prevent COVID-19 in
Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda. Sanofi and Regeneron’s PD-1 inhibitor Libtayo has received US Food and Drug Administration (FDA) approval in first-line, advanced ... advanced non-small cell lung cancer,”
FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

The FDA also granted Regeneron’s antibody cocktail REGN-COV2 an EUA in November 2020, for the treatment of mild-to-moderate COVID-19 patients who are at high risk of ... Regeneron’s EUA is based on data from the first 799 adults in an ongoing trial

More from news
Approximately 77 fully matching, plus 172 partially matching documents found.

Latest Intelligence

COVID-19: the race to find a vaccine

The same approach may work against SARSCoV-2. Regeneron Pharmaceuticals, leveraging a platform that spawned an Ebola treatment, is leading efforts to show that antibodies can neutralise SARS-CoV-2. ... A clinical trial of Regeneron’s drug is scheduled
As COVID-19 takes over the world, biopharma fights back

Evaluating IL-6 inhibitors: Roche’s Actemra and Sanofi and Regeneron’s Kevzara. Roche, Sanofi and Regeneron are also looking to repurpose their existing treatments and are currently testing their ... 19,” said George D Yancopoulos, co-founder,
20 for 2020 – Five pharma leaders to watch in 2020

The changes also mean Sanofi has downgraded some long-standing relationship in R&D – such as a fruitful tie-up with Regeneron that generated some of its top-selling drugs like ... Analysts think the deal could catapult Galapagos into the top tier of
Case study: See Below

Client:Sanofi Genzyme and Regeneron. Agency:Havas Lynx Group. Campaign:See Below. Timescale:N/A. Atopic dermatitis affects approximately 1-3% of adults worldwide. ... Topical corticosteroids are commonly used to treat atopic dermatitis. Sanofi Genzyme
Innovation and digital health comms recognised at Communiqué Awards

Innovation in Healthcare Communications. One high profile winning campaign was Havas Lynx Group’s ‘See Below’ on behalf of Sanofi Genzyme and Regeneron.

More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest appointments

Tiziana Life Sciences appoints clinical sciences VP

Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.
Regeneron taps Pfizer for CFO

Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients

In the latest episode of Impetus Digital's Fireside Chat, I talk with Sandra Graham-Mason, Director of Marketing at Regeneron Pharmaceuticals.
COUCH Health

Shire/Takeda. Pfizer. Amgen. Regeneron.
Lucid Group Communications Limited

Leo. Mead Johnson Nutrition. Mundipharma. Novartis. Pfizer. Regeneron.

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Principal Medical Writer: Varies on experience

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....